VenoValve and CoreoGraft Primary Investigators to Present at Webinar
IRVINE, CA / ACCESSWIRE / December 10, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that on Wednesday, December 16, 2020, at 1:00 Eastern time, Ladenburg Thalmann will host an R&D Showcase Webinar for Hancock Jaffe at which HJLI will provide updates on the VenoValve and CoreoGraft clinical studies.
The HJLI presentation will be led by Dr. Marc Glickman, HJLI's Senior Vice President and Chief Medical Officer, and will also feature Dr. Jorge Hernando Ulloa, the Principal Investigator for the VenoValve first-in-human trial, and Dr. Adrian Ebner, the Principal Investigator for the CoreoGraft first-in-human trial.
The Ladenburg Thalmann R&D Showcase Webinars allow for companies such as Hancock Jaffe with product candidates in clinical development or moving through regulatory approval pathways to provide in-depth, scientific presentations to investors.
Limited registration for live participation in the Webinar is available at https://zoom.us/webinar/register/5816075333364/WN_4GVCQ7GiTWKBxiYpbBXQGw. For those unable to attend the webinar live, a link to a replay of the webinar will be available after Thursday, December 17, 2020 in the Investor section of the Hancock Jaffe website.
About Hancock Jaffe Laboratories, Inc.
HJLI specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency; and the CoreoGraftÒ, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery. For more information, please visit HancockJaffe.com.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
SOURCE: Hancock Jaffe Laboratories, Inc.